PRIOR AUTHORIZATION POLICY
POLICY: Allergen Immunotherapy – Grass Pollen Sublingual Products Prior
Authorization Policy
• Grastek® (Timothy grass pollen allergen extract sublingual tablets –
ALK-Abello)
• Oralair® (Sweet Vernal, Orchard, Perennial Rye, Timothy, and
Kentucky Blue Grass mixed pollens allergen extract sublingual
tablets – Stallergenes/Greer)
REVIEW DATE: 10/09/2024
INSTRUCTIONS FOR USE
THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA
COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE
DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE
CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS
ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP
SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN
DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR
EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE
POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE
COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY
DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE
REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY
APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE
SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL
DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE
DETERMINATIONS. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES
ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS,
DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.
CIGNA NATIONAL FORMULARY COVERAGE:
OVERVIEW
Grastek and Oralair are grass pollen allergen extracts indicated for allergic rhinitis,
with or without conjunctivitis, that has been confirmed by a positive skin test or in
vitro test for pollen-specific immunoglobulin E (IgE) antibodies for Timothy grass or
cross reactive grass pollens (Grastek) or any of the five grasses contained in the
product (Oralair).1,2 These products are indicated in patients 5 through 65 years of
age.
Per product labeling, Grastek must be initiated 12 weeks before the expected onset
of each grass pollen season and Oralair must be initiated 4 months before the
expected onset of each grass pollen season.1,2 Both agents must be continued
throughout the season.
Clinical Efficacy
Page 1 of 3 - Cigna National Formulary Coverage - Policy:Allergen Immunotherapy – Grass Pollen Sublingual
Products Prior Authorization Policy
Pivotal trials of Grastek and Oralair included patients with grass pollen-induced
allergic rhinitis with or without conjunctivitis confirmed by either a positive skin prick
test to Timothy grass pollen or positive in vitro test.1,2
POLICY STATEMENT
Prior Authorization is recommended for prescription benefit coverage of Grastek and
Oralair. All approvals are provided for the duration noted below.
• Grastek® (Timothy grass pollen allergen extract sublingual tablets –
ALK-Abello)
• Oralair® (Sweet Vernal, Orchard, Perennial Rye, Timothy, and
Kentucky Blue Grass mixed pollens allergen extract sublingual tablets
– Stallergenes/Greer)
is(are) covered as medically necessary when the following criteria is(are)
met for FDA-approved indication(s) or other uses with supportive evidence
(if applicable):
FDA-Approved Indication
1. Grass Pollen-Induced Allergic Rhinitis. Approve for 1 year if the patient meets
ALL of the following (A, B and C):
A) Patient is ≥ 5 years of age; AND
B) The timing of prescribing meets ONE of the following (i or ii):
i. Grastek: Therapy is initiated 12 weeks prior to the expected onset of the
grass pollen season or therapy is being dosed daily continuously for
consecutive grass pollen seasons; OR
ii. Oralair: Therapy is initiated 4 months prior to the expected onset of the
grass pollen season; AND
C) The diagnosis of grass pollen-induced allergic rhinitis is confirmed by meeting
ONE of the following (i or ii):
i. Patient has a positive skin test response to a grass pollen from the Pooideae
subfamily of grasses (this includes, but is not limited to: sweet vernal,
Kentucky blue grass, Timothy grass, orchard, or perennial rye grass); OR
ii. Patient has a positive in vitro test (i.e., a blood test) for allergen-specific
immunoglobulin E antibodies for a grass in the Pooideae subfamily of
grasses (see examples above).
CONDITIONS NOT COVERED
• Grastek® (Timothy grass pollen allergen extract sublingual tablets –
ALK-Abello)
• Oralair® (Sweet Vernal, Orchard, Perennial Rye, Timothy, and
Kentucky Blue Grass mixed pollens allergen extract sublingual tablets
– Stallergenes/Greer)
3 Pages - Cigna National Formulary Coverage - Policy:Allergen Immunotherapy – Grass Pollen Sublingual
Products Prior Authorization Policy
is(are) considered experimental, investigational or unproven for ANY other
use(s) including the following (this list may not be all inclusive; criteria will
be updated as new published data are available):
1. Concurrent Use of Grastek or Oralair with Subcutaneous Allergen
Immunotherapy or Sublingual Allergen Immunotherapy. Note: This
includes allergy shots as well as Odactra® [house dust mite {Dermatophagoides
farina and Dermatophagoides pteronyssinus} allergen extract sublingual tablets],
Ragwitek® [short ragweed pollen allergen extract sublingual tablets]). The efficacy
of Grastek and Oralair has not been evaluated in patients who are receiving
concomitant allergen immunotherapy.1 Approved product labeling for both
Grastek and Oralair states that concomitant dosing with other allergen
immunotherapy may increase the risk of local or systemic adverse events to either
subcutaneous or sublingual allergen immunotherapy.
REFERENCES
1. Grastek® sublingual tablets [prescribing information]. Swindon, Wiltshire, United Kingdom: ALK-
Abello A/S; September 2022.
2. Oralair® sublingual tablets [prescribing information]. Lenoir, NC: Greer; November 2023.
HISTORY
Type of Summary of Changes Review
Revision Date
Annual No criteria changes. 09/13/2023
Revision
Annual No criteria changes. 10/09/2024
Revision
"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are
provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance
Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health
Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.
3 Pages - Cigna National Formulary Coverage - Policy:Allergen Immunotherapy – Grass Pollen Sublingual
Products Prior Authorization Policy